Clorazepate is a long-acting benzodiazepine indicated for anxiety disorders, acute alcohol withdrawal, and as adjunctive therapy in epilepsy. It is a prodrug that is converted to desmethyldiazepam (nordiazepam) in the stomach, providing sustained anxiolytic and anticonvulsant effects with once or twice daily dosing.
Clinical Overview
Primary Clinical Applications
Clorazepate is effective for generalized anxiety disorder, panic disorder, acute alcohol withdrawal syndrome, and as adjunctive therapy for partial seizures. Its long duration of action makes it suitable for conditions requiring sustained therapeutic effects and may reduce rebound anxiety between doses.
Mechanism and Pharmacological Profile
Clorazepate is rapidly converted to the active metabolite desmethyldiazepam, which enhances GABA activity at benzodiazepine receptors. The long half-life of the active metabolite (30-100 hours) provides sustained therapeutic effects but also increases the risk of accumulation, particularly in elderly patients.
Clinical Considerations
The extended duration of action allows for less frequent dosing compared to shorter-acting benzodiazepines, which may improve adherence and provide more consistent symptom control. However, the long half-life also means that withdrawal symptoms may be delayed and prolonged when discontinuing treatment.
Key Clinical Points
A prodrug converted in the stomach
Clorazepate is inactive as administered and is converted to desmethyldiazepam by gastric acid. Conditions or drugs that substantially raise gastric pH can therefore reduce conversion and blunt the clinical effect.
Active metabolite lasts 30 to 100 hours
The very long half-life of desmethyldiazepam gives sustained cover and once or twice daily dosing, but drives significant accumulation over repeated doses.
Structured alcohol withdrawal schedule
The label sets out a defined four-day reducing regimen from 30 to 60 mg on day one down to 15 to 30 mg by day four, then further reduction. The long half-life provides a degree of self-taper.
Accumulation risk in older adults
Falls, confusion, and oversedation reflect metabolite accumulation rather than the parent drug. Starting doses of 7.5 to 15 mg daily with slow titration are recommended.
Delayed and prolonged withdrawal
Withdrawal may begin later and last longer than with shorter-acting benzodiazepines, which can lead clinicians to misattribute late symptoms to relapse rather than discontinuation.
Prescribing Information
Dosing & Administration
Anxiety Disorders – Adults:
- Initial: 15 mg at bedtime or 7.5 mg twice daily
- Range: 15-60 mg daily in divided doses
- Maximum: 60 mg daily
Elderly or Debilitated:
- Initial: 7.5-15 mg daily
- Titrate slowly based on response and tolerance
Acute Alcohol Withdrawal:
- Day 1: 30 mg initially, then 30-60 mg in divided doses
- Day 2: 45-90 mg in divided doses
- Day 3: 22.5-45 mg in divided doses
- Day 4: 15-30 mg in divided doses
- Thereafter: Gradually reduce to 7.5-15 mg daily
Epilepsy (Adjunctive):
- Adults: 7.5 mg three times daily, may increase by 7.5 mg weekly (maximum 90 mg daily)
Indications
- Management of anxiety disorders
- Short-term relief of anxiety symptoms
- Acute alcohol withdrawal syndrome
- Adjunctive therapy in management of partial seizures
Contraindications
- Hypersensitivity to benzodiazepines
- Acute narrow-angle glaucoma
- Depressive neuroses or psychotic reactions
- Pregnancy (first trimester)
Warnings & Precautions
- Boxed Warning: Risk of abuse, misuse, dependence; respiratory depression with opioids
- Physical dependence: Risk increases with dose and duration
- Withdrawal syndrome: Taper gradually, may be severe due to long half-life
- Respiratory depression: Enhanced with concurrent CNS depressants
- Cognitive impairment: May affect memory and concentration
- Falls risk: Particularly in elderly due to long-acting metabolite
Drug Interactions
- Opioids: Increased risk of respiratory depression and death
- CNS depressants: Enhanced sedation and respiratory depression
- Alcohol: Dangerous potentiation of effects
- CYP3A4 inhibitors: May increase active metabolite levels
Adverse Reactions
Common:
- Drowsiness, dizziness, fatigue, ataxia
- Confusion, memory impairment
Serious:
- Respiratory depression, severe sedation, dependence
Special Populations
- Elderly: Increased sensitivity, higher fall risk due to long-acting metabolite
- Hepatic Impairment: Use caution, may require dose reduction
- Pregnancy: Category D – avoid in pregnancy
- Long half-life: Risk of accumulation with repeated dosing
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
